Literature DB >> 7875212

Regulation of 4-1BB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4.

K E Pollok, S H Kim, B S Kwon.   

Abstract

4-1BB expression increased gradually following T cell activation, and by day 3 post-stimulation with immobilized anti-CD3 (anti-CD3i) or concanavalin A (Con A), splenic T cells were routinely 35-45% 4-1BB+ by flow cytometric analysis. 4-1BB was expressed on activated CD8+, CD4+, CD28+ and CD45RB+ T cells. Optimal 4-1BB expression was seen by day 6 post-stimulation and was cell density dependent. When T cells were cultured for 6 days at 1 x 10(6)/well in a 24-well plate with anti-CD3i, 82% of the cells were 4-1BB+. In contrast, at lower cell densities (4 x 10(5), 2 x 10(5) and 1 x 10(5)), optimal 4-1BB expression was observed only if the cultures were supplemented with recombinant interleukin-2 (IL-2) or recombinant IL-4 (IL-4). In agreement, with these results, modes of inducing endogenous IL-2 production such as cross-linking the costimulatory molecule, CD28, or the addition of syngeneic accessory cells to T cells activated with anti-CD3i, resulted in high levels of 4-1BB expression. The addition of interleukin-1 alpha (IL-1 alpha) or interferon-gamma (IFN-gamma) did not increase 4-1BB expression on anti-CD3i-activated T cells. In addition, if T cells were incubated with IL-2, IL-4, IL-1 alpha, IFN-gamma or anti-CD28 alone, no 4-1BB expression was induced. T cells activated with soluble anti-CD3 (anti-CD3s) in the presence of IL-2, IL-4, or accessory cells, did not express higher levels of 4-1BB on their cell surface. These data suggest that initial events crucial for efficient T cell activation, such as signals delivered through the T cell receptor/CD3 complex and the CD28 molecule, are instrumental in regulating subsequent 4-1BB expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7875212     DOI: 10.1002/eji.1830250227

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes.

Authors:  Kwang-Mi Kim; Ho Won Kim; Jae-Ouk Kim; Kyoung-Min Baek; Joong Gon Kim; Chang-Yuil Kang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant.

Authors:  Jung D Kim; Chang H Kim; Byoung S Kwon
Journal:  Mol Cells       Date:  2011-01-11       Impact factor: 5.034

3.  A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis.

Authors:  G Nocentini; L Giunchi; S Ronchetti; L T Krausz; A Bartoli; R Moraca; G Migliorati; C Riccardi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  Immunotherapy targeting 4-1BB and its ligand.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

5.  Pancreatic lipase-related protein 2 (PLRP2) induction by IL-4 in cytotoxic T lymphocytes (CTLs) and reevaluation of the negative effects of its gene ablation on cytotoxicity.

Authors:  Bryce N Alves; Jeff Leong; David L Tamang; Viki Elliott; Jillian Edelnant; Doug Redelman; Cherie A Singer; Andrew R Kuhn; Rita Miller; Mark E Lowe; Dorothy Hudig
Journal:  J Leukoc Biol       Date:  2009-05-18       Impact factor: 4.962

6.  4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques.

Authors:  Alexandra J Spencer; Julie Furze; Jared D Honeycutt; Alice Calvert; Saroj Saurya; Stefano Colloca; David H Wyllie; Sarah C Gilbert; Migena Bregu; Matthew G Cottingham; Adrian V S Hill
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

7.  Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.

Authors:  S Michael Chin; Christopher R Kimberlin; Zygy Roe-Zurz; Pamela Zhang; Allison Xu; Sindy Liao-Chan; Debasish Sen; Andrew R Nager; Nicole Schirle Oakdale; Colleen Brown; Feng Wang; Yuting Yang; Kevin Lindquist; Yik Andy Yeung; Shahram Salek-Ardakani; Javier Chaparro-Riggers
Journal:  Nat Commun       Date:  2018-11-08       Impact factor: 14.919

8.  Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells.

Authors:  Christophe Glorieux; Peng Huang
Journal:  Cancer Commun (Lond)       Date:  2019-07-09

9.  Rapid manufacturing of non-activated potent CAR T cells.

Authors:  Saba Ghassemi; Joseph S Durgin; Selene Nunez-Cruz; Jai Patel; John Leferovich; Marilia Pinzone; Feng Shen; Katherine D Cummins; Gabriela Plesa; Vito Adrian Cantu; Shantan Reddy; Frederic D Bushman; Saar I Gill; Una O'Doherty; Roddy S O'Connor; Michael C Milone
Journal:  Nat Biomed Eng       Date:  2022-02-21       Impact factor: 29.234

Review 10.  Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.

Authors:  Daniele E Mascarelli; Rhubia S M Rosa; Jessica M Toscaro; Isadora F Semionatto; Luciana P Ruas; Carolinne T Fogagnolo; Gabriel C Lima; Marcio C Bajgelman
Journal:  Front Cell Dev Biol       Date:  2021-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.